Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 6, 2006 - Issue 6
Submit an article Journal homepage
87
Views
16
CrossRef citations to date
0
Altmetric
Drug Profile

Ibritumomab tiuxetan for non-Hodgkin’s lymphoma

Patrick B Johnston Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. [email protected]
,
Cara Bondly Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. [email protected]
&
Ivana NM Micallef Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. [email protected]
Pages 861-869 | Published online: 10 Jan 2014

References

  • McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol.16, 2825–2833 (1998).
  • McLaughlin P, White CA, Grillo-Lopez AJ et al. Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology12, 1763–1770, 1775–1777 (1998).
  • Micallef IN. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma. Clin. Lymphoma5(Suppl. 1) S27–S32 (2004).
  • Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma: from clinical trials to clinical practice. J. Nucl. Med.43, 1507–1529 (2002).
  • Wiseman GA, White CA, Sparks RB et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Crit. Rev. Oncol. Hematol.39, 181–194 (2001).
  • Wiseman G. Urinary clearance of 90Y activity following Zevalin radioimmunotherapy of B-cell non-hodgkins lymphoma. J. Nucl. Med.42, 268 (2001).
  • Zevalin (ibritumomab tiuxetan) prescribing information. Biogen Idec Inc , Cambridge, MA, USA. (2002).
  • Gregory SA. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin). Semin. Oncol.30, 17–22 (2003).
  • Grillo-Lopez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev. Anticancer Ther.2, 485–493 (2002).
  • Hagenbeek A, Lewington V. Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin) in lymphoma. Ann. Oncol.16, 786–792 (2005).
  • Grillo-Lopez AJ. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. Semin. Oncol.32, S44–S49 (2005).
  • Grillo-Lopez AJ, Chinn P, Morena R et al. Phase I study of IDEC-Y2B8: 90-yttrium labeled antiCD20 monoclonal antibody therapy of relapsed non-Hodgkins lymphoma. Blood86, 55a (1995).
  • Knox SJ, Goris ML, Trisler K et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin. Cancer Res.2, 457–470 (1996).
  • Wiseman GA, White CA, Stabin M et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur. J. Nucl. Med.27, 766–777 (2000).
  • Gordon LI, Molina A, Witzig T et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood103, 4429–4431 (2004).
  • Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.17, 3793–3803 (1999).
  • Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.20, 2453–2463 (2002).
  • Gordon LI, Witzig T, Molina A et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma5, 98–101 (2004).
  • Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol.20, 3262–3269 (2002).
  • Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood99, 4336–4342 (2002).
  • Schilder R, Molina A, Bartlett N et al. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma and mild thrombocytopenia. Cancer Biother. Radiopharm.19, 478–481 (2004).
  • Schilder RJ, Emmanouilides C, Vo K et al. Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL. J. Clin. Oncol. (Meeting Abstracts)23, 6562 (2005).
  • Shipley DL, Greco FA, Spigel DR et al. Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: update of a Minnie Pearl Cancer Research Network phase II trial. J. Clin. Oncol.23, 579s (2005).
  • Witzig T, Wiseman G, Geyer S et al. A Phase I trial of two-sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non-hodgkin’s lymphoma. Blood102, 406a (2003).
  • Wiseman GG, Porrata L, Inwards D et al. Ongoing results of a phase I trial of two sequential doses of Y-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed low-grade non-hodgkin lymphoma. Ann. Oncol.16, 135 (2005).
  • Morschhauser F, Huglo D, Martinelli G et al. Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. ASH Annual Meeting Abstracts104, 130 (2004).
  • Hamlin PA, Moskowitz CH, Wegner BC et al. Early safety and efficacy analysis of a phase ii study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (Zevalin®) for elderly high risk patients with untreated DLBCL. ASH Annual Meeting Abstracts106, 926 (2005).
  • Oki Y, Pro B, Delpassand E et al. A Phase II study of yttrium 90 (90y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). ASH Annual Meeting Abstracts104, 2632 (2004).
  • Flinn IW, Kahl BS, Frey E et al. Dose finding trial of yttrium 90 (90y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-hodgkin’s lymphoma (NHL). ASH Annual Meeting Abstracts104, 897 (2004).
  • Winter JN, Inwards DJ, Spies S et al.90Y ibritumomab tiuxetan (Zevalin®; 90YZ) doses higher than .4 mCi/kg may be safely combined with high-dose beam and autotransplant: the role for dosimetry. Blood104, 1162 (2004).
  • Krishnan AY, Nademanee A, Forman SJ et al. The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin’s lymphoma (NHL). J. Clin. Oncol. (Meeting Abstracts)23, 6566 (2005).
  • Nademanee A, Forman S, Molina A et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood106, 2896–2902 (2005).
  • Vose J, Bierman P, Lynch J et al. Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT). Blood102, 30a (2003).
  • Witzig TE, White CA, Gordon LI et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hdogkin’s lymphoma. J. Clin. Oncol.21, 1263–1270 (2003).
  • Czuczman MSW, TE Gaston I, Skikne BS et al. Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). Blood100, 357a (2002).
  • Ansell SM, Ristow KM, Habermann TM et al. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin’s lymphoma. J. Clin. Oncol.20, 3885–3890 (2002).
  • Ansell SM, Schilder RJ, Pieslor PC et al. Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin’s lymphoma: a review of the literature. Clin. Lymphoma5, 202–204 (2004).

Website

  • The National Comprehensive Cancer Network clinical practice guidelines in oncology www.nccn.org/professionals/physician_gls/default.asp
  • The US Food and Drug Administration website www.fda.gov

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.